28 Sep 2010
The Second International Malaria Vaccines for the World Conference was the follow-up to the first meeting, held in London in 2007. This second conference also offered researchers a fresh forum to discuss the current status of new malaria vaccine initiatives, vaccine candidates, and clinical trials.

MVI Involvement in MVW Conference

MVI sponsored two symposia at the conference:

  • The MVI portfolio: Diverse approaches to malaria vaccine development
  • African researchers tackle an African affliction: Recent milestones and the way forward for the RTS,S malaria vaccine candidate

The MVI portfolio: Diverse approaches to malaria vaccine development
Tuesday, September 28, 2010
2:00–4:00 p.m.
Location: Kellogg Conference Hotel

This session highlighted the variety of projects and approaches in MVI’s portfolio. Recent findings from two studies testing liver-stage antigens were presented, as well as preliminary GIA results for the EBA-175 ligand for blood-stage vaccines. The session also provided an overview of the first transmission-blocking vaccine (TBV) approach in MVI’s portfolio, utilizing the AnAPN1 mosquito antigen and update on the status of the membrane-feeding assay (MFA) service lab being established at the National Institute for Allergy and Infectious Diseases (NIAID).

Sponsors: MVI

African researchers tackle an African affliction: Recent milestones and the way forward for the RTS,S malaria vaccine candidate
Wednesday, September 29, 2010
11:00 a.m.–1:00 p.m.
Location: Kellogg Conference Hotel

This session focused on the world’s most advanced malaria vaccine candidate, RTS,S, developed in partnership between MVI, GSK Biologicals, and African research centers. The session summarized the history of the RTS,S vaccine, the scientific concepts and the clinical data available so far. An update on the Phase 3 clinical trial program currently taking place in Africa was also be provided. The session also outlined the steps that will need to be taken to prepare international organizations and African countries to determine if and how to implement use of the RTS,S malaria vaccine candidate.

Sponsors: MVI